Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial

ESMO 2012

28 Sep - 2 Oct 2012

Published: 29 Sep 2012

Views: 3723

Rating:

Save

Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain

Data presented at a press conference during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna Dr Luis Paz-Ares explained that treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC).

Related Videos

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy...

Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )

Tusamitamab ravtansine versus docetaxel in previously treated advanced...

Prof Benjamin Besse - Gustave Roussy, Paris, France

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial ( Prof Benjamin Besse - Gustave Roussy, Paris, France )

Cemiplimab monotherapy could be a new treatment option for first line advanced...

Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients ( Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Amivantamab-lazertinib continue to show benefit as a first-line standard-of...

Dr Marina Garassino - University of Chicago, Chicago, USA

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof...

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

More from ecancer